Related Experiment Videos
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine
Elaine Weiner1, Robert R Conley, M Patricia Ball
1Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA.
Summary
Adding risperidone to clozapine treatment showed modest benefits for partial responders with schizophrenia. This adjunctive therapy improved positive and negative symptoms in some analyses, with no significant safety concerns besides elevated prolactin.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Partial response to clozapine presents a significant clinical challenge in treating schizophrenia and schizoaffective disorder.
- Limited evidence exists to guide optimal treatment strategies for patients with partial clozapine response.
- Optimizing clozapine therapy is crucial for managing treatment-resistant psychiatric conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of adjunctive risperidone in patients with schizophrenia or schizoaffective disorder receiving optimal clozapine treatment.
- To determine if risperidone augmentation can improve outcomes in a well-defined, treatment-resistant population.
- To assess the impact of adjunctive risperidone on positive, negative, and total psychiatric symptoms.
Main Methods:
- A 16-week, double-blind, placebo-controlled, randomized clinical trial involving 69 inpatients and outpatients.
- Participants were diagnosed with DSM-IV schizophrenia or schizoaffective disorder and were on stable clozapine treatment.
- Patients were randomized to receive either risperidone (n=33) or placebo (n=36) as an adjunct to clozapine.
Main Results:
- No significant group differences were observed for the primary response criteria.
- Modest, significant improvements favoring risperidone were found in completer analyses for positive symptoms (BPRS) and total scores.
- Significant improvement in negative symptoms (SANS total score) favored the risperidone group; elevated prolactin was noted, but no significant safety concerns on other measures.
Conclusions:
- Adjunctive risperidone may offer modest benefits for patients with treatment-resistant schizophrenia or schizoaffective disorder who are partial responders to clozapine.
- The findings suggest a potential role for risperidone augmentation in specific patient subgroups, warranting further investigation.
- While generally safe, the impact on prolactin levels should be considered in clinical practice.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...